The Investor's Guide to Buying GLP-1 Stocks

How to Invest in GLP-1 Stocks

By Rachel Warren – Updated Oct 29, 2025 at 10:18 PM | Fact-checked by Robin Hartill, CFP

Key Points

GLP-1 drugs were initially developed for type 2 diabetes but are now widely used to treat obesity.
Novo Nordisk and Eli Lilly lead in GLP-1 drug production, with others like Viking Therapeutics emerging.
Investors can consider GLP-1 stocks or diversify risk via funds like Roundhill GLP-1 & Weight Loss ETF.

GLP-1 drugs are transforming healthcare in the modern age. Initially developed for type 2 diabetes, these drugs have demonstrated significant weight loss benefits. GLP-1s are changing the way healthcare providers think about obesity management beyond traditional surgical approaches.

Loading paragraph...

Pharmacists reviewing medication. — Image source: Getty Images.

Loading paragraph...

Biotech vs. Pharma: What's the Difference?

While there is a lot of overlap between biotech and pharma, there are some key differences.

Best Medical Device Stocks to Buy for 2025

The medical device market is expected to grow to almost $800 billion by 2030. Here's a list of the year's best opportunities.

Pharmaceutical tariffs: Which countries does the U.S. import the most from?

The United States has a $115.5 billion trade deficit in pharmaceutical products, read on for more drug manufacturing stats.

These Are Billionaires’ Favorite Healthcare Stocks

The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.

Loading paragraph...

Loading faq...

About the Author

Rachel Warren is a contributing Motley Fool stock market analyst covering pharmaceuticals, biotechnology, medical devices, information technology, and consumer goods. Prior to The Motley Fool, Rachel was a paralegal and legal administrator. She holds a bachelor’s degree in paralegal studies from Liberty University School of Law.

TMFRachelW

Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Merck. The Motley Fool recommends Novo Nordisk, Roche Holding AG, and Viking Therapeutics. The Motley Fool has a disclosure policy.